



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/658,482	09/09/2003	Daryl T. Baldwin	P1974R1	3368	
9157	7590 12/08/2005		EXAM	INER	
GENENTECH, INC.			SZPERKA, MICHAEL EDWARD		
	FRANCISCO, CA 9408	0	ART UNIT	PAPER NUMBER	
	,		1644		

DATE MAILED: 12/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		, Application No.	Applicant(s)		
	Netice to Commit	10/658, 482 Examiner	Baldwin et al.		
Notice to Comply	Examiner	Art Unit			
		Michael Szperka	1644		
CC	OTICE TO COMPLY WITH REQUESTION OF THE SEQUES SCLOSURES	UIREMENTS FOR PATENT UENCE AND/OR AMINO A	APPLICATIO	NS CE	
is a	plicant must file the items indicated belo attached to avoid abandonment under 3 ovisions of 37 CFR 1.136(a)).	ow within the time period set the C 5 U.S.C. § 133 (extensions of tim	Office action to when the may be obtained	nich the Notice ed under the	
The the	The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):				
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).				
	2. This application does not contain, as Listing" as required by 37 C.F.R. 1.821	s a separate part of the disclosure	on paper copy, a	a "Sequence	
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
	4. A copy of the "Sequence Listing" in content of the computer readable form 1.823, as indicated on the attached co	does not comply with the require	ments of 37 C.F.I	wever, the R. 1.822 and/or	
	5. The computer readable form that ha and/or unreadable as indicated on the readable form must be submitted as re	attached CRF Diskette Problem F	nas been found to Report. A Substit	o be damaged ute computer	
	6. The paper copy of the "Sequence Listing" as required by 37 C	sting" is not the same as the composer. 1.821(e).	puter readable fro	om of the	
	7. Other: see enclosed communication	J			

- Applicant Must Provide:

 An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



UNITED STATES DEPARTMENT OF COMMERCE

DATE MAILED:

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.	
				EXAMINER	
			ART UNIT	PAPER	
				11102005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The reason is that the paper copy and computer readable form of the sequence listing are not present in the instant application.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR §1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is 571-272-2934. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Szperka, Ph.D. Patent Examiner Technology Center 1600 November 10, 2005 Patrick J. Nolan, Ph.D. Primary Examiner Technology Center 1600